Quick Links

neurological disease

What happens after the ALS ice bucket challenge?

Amyotrophic lateral sclerosis (ALS), also known as “Lou Gehrig’s Disease,” is a devastating fatal disease of the nervous system that kills two to five Canadians every day. On September 19th and 20th, the Montreal Neurological Institute and Hospital (The Neuro), at McGill University and the McGill University Health Centre will host the 10th Annual ALS Symposium of the Fondation André-Delambre. Nearly one hundred researchers and clinicians from several countries will come together to discuss recent progress in ALS research.

Published: 19Sep2014

International study yields important clues to the genetics of epilepsy

An international team of researchers has discovered a significant genetic component of Idiopathic Generalized Epilepsy (IGE), the most common form of epilepsy. Epilepsy is a neurological disorder characterized by sudden, uncontrolled electrical discharges in the brain expressed as a seizure. The new research, published in this week’s issue of EMBO Reports, implicates a mutation in the gene for a protein, known as cotransporter KCC2. 

Published: 16Jun2014

Noisy brain signals: How the schizophrenic brain misinterprets the world

People with schizophrenia often misinterpret what they see and experience in the world. New research provides insight into the brain mechanisms that might be responsible for this misinterpretation.

Published: 2Apr2014

Blocking overactive receptor in Alzheimer’s recovers memory loss and more

A new study shows that memory pathology in older mice with Alzheimer’s disease can be reversed with treatment. The study by researchers from the Montreal Neurological Institute and Hospital - The Neuro, at McGill University and at Université de Montréal found that blocking the activity of a specific receptor in the brain of mice with advanced Alzheimer’s disease (AD) recovers memory and cerebrovascular function. The results, published in the Journal of Neuroinflammation in May, also suggest an underlying mechanism of AD as a potential target for new therapies.

Published: 17Jun2013

June is ALS Awareness Month

What is ALS?
Amyotrophic Lateral Sclerosis (ALS) also known as Lou Gehrig’s disease, is a neurodegenerative disease in which progressive muscle weakness leads to paralysis. ALS is a result of the death of motor neurons (nerve cells) in the brain and spinal cord that control voluntary muscle movement. Most people survive less than five years following diagnosis, but a small percentage of patients live for ten years or even longer. So far, there is no cure. About 3,000 Canadian adults have ALS and less than 1 in 10 patients have a family history of the disease. 

Published: 13Jun2013

Unleashing the watchdog protein

Research opens door to new drug therapies for Parkinson’s disease

McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson’s disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The Neuro, and  Dr. Kalle Gehring  in the Department of Biochemistry at the Faculty of Medicine, have discovered the three-dimensional structure of the protein Parkin.

Published: 9May2013

Addiction: abnormal communication in the brain

January 29, 2013 - Addiction to cigarettes, drugs and other stimulants has been linked in the past to the brain’s frontal lobes, but now there is scientific evidence that indicates where in the frontal cortex addiction takes hold and how.  Addiction could be a result of abnormal communication between two areas of the frontal lobes linked to decision-making.  The discovery will undoubtedly stimulate clinical work on new therapies for millions of people who suffer from addiction.

Published: 5Feb2013

Technology has unprecedented ability to detect and diagnose Alzheimer’s

January 28, 2013 - A revolutionary technology has the ability to detect and diagnose Alzheimer’s disease with unprecedented accuracy. The computerized technique known as SNIPE analyzes magnetic resonance imaging (MRI) scans to capture patterns of atrophy specific to the disease in brain structures, specifically the hippocampus and entorhinal cortex. Diagnosing Alzheimer’s disease (AD) is still an inexact science, relying mainly on the patient's symptoms and performance on memory tests. Detecting pre-clinical AD, before symptoms appear, is extremely difficult.

Published: 5Feb2013

Pages